SEK 11.96
+0.14 (+1.18%)
SEK · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CINPHA.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 4 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan GlurateNCT05469854Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (AUCinf)Randomized · Quadruple-masked · Basic science | Phase 1 | Recruiting | Drug: Linaprazan glurate, Placebo | Pharmacokinetics, Cardiodynamic ECG, Safety, and Tolerability, GERD | 121 | 2026-11-30 | in 103 d | 2026-06-17 |
| A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)NCT07037875Healing of EE at Week 4 as assessed by endoscopy in participants with Baseline EE LA grades C/D.Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Linaprazan glurate 50 mg Twice Daily (BID), Linaprazan Glurate 50 mg Once Daily (QD), Lansoprazole 30 mg Once Daily (QD) | GERD (Gastroesophageal Reflux Disease) | 500 | Aug 2026 | ≤ 12 d | 2026-08-04 |
| A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)NCT07313774Maintained healing of EE after 24 weeks as assessed by central reading of endoscopy.Randomized · Quadruple-masked · Other | Phase 3 | Withdrawnsponsor's stated reason: Strategic desicion by Sponsor | Drug: Linaprazan glurate - High dose, Linaprazan glurate - Low dose, Lansoprazole - Marketed approved dose | GERD (Gastroesophageal Reflux Disease) | 0 | Sep 2028 | ≤ 773 d | 2026-05-28 |
| A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of AmoxicillinNCT07308041Characterization of the PK of amoxicillin following a repeated dose before and after repeated administration of linaprazan glurate (AUC)Open-label · Treatment | Phase 1 | Completed | Drug: Drug Drug Interaction | Drug Interaction, GERD (Gastroesophageal Reflux Disease), Safety, and Tolerability | 12 | 2025-12-22actual | — | 2026-02-27 |
| Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of MidazolamNCT05633147results2025-01-03Period I, Part I - Linaprazan Glurate and Linaprazan PK Parameters With and Without Co-administration of Clarithromycin - AUC0-infOpen-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Linaprazan glurate, Drug drug interaction (DDI) - Clarithromycin (Part I), Drug drug interaction (DDI) - Midazolam (Part 2) | Safety Issues, Pharmacokinetics, Drug Interaction, Tolerability | 35 | 2023-05-30actual | — | 2025-01-03 |
| Investigate Linaprazan Glurate/Linaprazan in Healthy SubjectsNCT05742984results2025-05-07AUC0-24h Linaprazan (QD)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: linaprazan glurate 25 mg QD, linaprazan glurate 50 mg QD, linaprazan glurate 75 mg QD, linaprazan glurate 25 mg BID, linaprazan glurate 50 mg BID, linaprazan glurate 75 mg BID | GERD | 75 | 2023-03-24actual | — | 2025-05-07 |
| Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference FormulationNCT05627518results2025-04-03Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratios of AUCinf and AUClastRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Linaprazan glurate | Safety, Bioavailability, Pharmacokinetics | 67 | 2022-12-30actual | — | 2025-04-03 |
| A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With LansoprazoleNCT05055128results2023-11-01Number of Patients With Esophageal Mucosa HealingRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy | Erosive Esophagitis | 248 | 2022-09-01actual | — | 2026-07-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose StudyNCT03105375Occurrence and frequency of AEs, changes in laboratory parameters, vital signs and physical examination after single and multiple doses of X842. Summary statistics will be applied.Non-randomized · Open-label · Basic science | Early Phase 1 | Completed | Drug: Single ascending dose of X842, Multiple ascending dose of X842, Losec | Healthy Volunteers | 39 | 2017-10-12actual | — | 2026-06-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19